Mayrdorfer M, et al. Exploring the complexity of death-censored kidney allograft failure. J Am Soc Nephrol 2021; 32:1513–1526. doi: 10.1681/asn.2020081215

• PubMed
Mayrdorfer M, Exploring the complexity of death-censored kidney allograft failure. J Am Soc Nephrol 2021; 32:1513–1526. doi: 10.1681/asn.2020081215)| false
• Search Google Scholar
• Export Citation

Lefaucheur C, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381:313–319. doi: 10.1016/S0140-6736(12)61265-3

• PubMed
Lefaucheur C, Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381:313–319. doi: 10.1016/S0140-6736(12)61265-3)| false
• Search Google Scholar
• Export Citation

Nankivell BJ, et al. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 2018; 18:364–376. doi: 10.1111/ajt.14609

• PubMed
Nankivell BJ, The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion. Am J Transplant 2018; 18:364–376. doi: 10.1111/ajt.14609)| false
• Search Google Scholar
• Export Citation

Doberer K, et al. CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2021; 105:451–457. doi: 10.1097/tp.0000000000003247

• PubMed
Doberer K, CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation 2021; 105:451–457. doi: 10.1097/tp.0000000000003247)| false
• Search Google Scholar
• Export Citation

Heeger PS, et al. Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol 2024; 20:218–232. doi: 10.1038/s41581-023-00791-0

• PubMed
Heeger PS, Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol 2024; 20:218–232. doi: 10.1038/s41581-023-00791-0)| false
• Search Google Scholar
• Export Citation

Krejcik J, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016; 128:384–394. doi: 10.1182/blood-2015-12-687749

• PubMed
Krejcik J, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 2016; 128:384–394. doi: 10.1182/blood-2015-12-687749)| false
• Search Google Scholar
• Export Citation

Malavasi F, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88:841–886. doi: 10.1152/physrev.00035.2007

• PubMed
Malavasi F, Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev 2008; 88:841–886. doi: 10.1152/physrev.00035.2007)| false
• Search Google Scholar
• Export Citation

Deaglio S, et al. Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 1996; 156:727–734. https://journals.aai.org/jimmunol/article-abstract/156/2/727/110915/Human-CD38-ligand-A-120-KDA-protein-predominantly

• PubMed
Deaglio S, Human CD38 ligand. A 120-KDA protein predominantly expressed on endothelial cells. J Immunol 1996; 156:727–734. https://journals.aai.org/jimmunol/article-abstract/156/2/727/110915/Human-CD38-ligand-A-120-KDA-protein-predominantly)| false
• Search Google Scholar
• Export Citation

Boslett J, et al. Characterization of CD38 in the major cell types of the heart: Endothelial cells highly express CD38 with activation by hypoxia-reoxygenation triggering NAD(P)H depletion. Am J Physiol Cell Physiol 2018; 314:C297–C309. doi: 10.1152/ajpcell.00139.2017

• PubMed
Boslett J, Characterization of CD38 in the major cell types of the heart: Endothelial cells highly express CD38 with activation by hypoxia-reoxygenation triggering NAD(P)H depletion. Am J Physiol Cell Physiol 2018; 314:C297–C309. doi: 10.1152/ajpcell.00139.2017)| false
• Search Google Scholar
• Export Citation

Musso T, et al. CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001; 69:605–612. https://jlb.onlinelibrary.wiley.com/doi/full/10.1189/jlb.69.4.605

• PubMed
Musso T, CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines. J Leukoc Biol 2001; 69:605–612. https://jlb.onlinelibrary.wiley.com/doi/full/10.1189/jlb.69.4.605)| false
• Search Google Scholar
• Export Citation

Kang B-N, et al. Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: Role of NF-kappaB and sensitivity to glucocorticoids. FASEB J 2006; 20:1000–1002. doi: 10.1096/fj.05-4585fje

• PubMed
Kang B-N, Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: Role of NF-kappaB and sensitivity to glucocorticoids. FASEB J 2006; 20:1000–1002. doi: 10.1096/fj.05-4585fje)| false
• Search Google Scholar
• Export Citation

Ramaschi G, et al. Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood 1996; 87:2308–2313. https://ashpublications.org/blood/article/87/6/2308/124563/Expression-of-cyclic-ADP-ribose-synthetizing-CD38

• PubMed
Ramaschi G, Expression of cyclic ADP-ribose-synthetizing CD38 molecule on human platelet membrane. Blood 1996; 87:2308–2313. https://ashpublications.org/blood/article/87/6/2308/124563/Expression-of-cyclic-ADP-ribose-synthetizing-CD38)| false
• Search Google Scholar
• Export Citation

Mayer KA, et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med 2024; 391:122–132. doi: 10.1056/NEJMoa2400763

• PubMed
Mayer KA, A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med 2024; 391:122–132. doi: 10.1056/NEJMoa2400763)| false
• Search Google Scholar
• Export Citation